$1.71 Billion is the total value of Sofinnova Investments, Inc.'s 72 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Natera Inc | $289,785,000 | -16.2% | 3,102,960 | 0.0% | 16.93% | -17.3% | |
| KRTX | Karuna Therapeutics, Inc. | $255,853,000 | +7.1% | 1,953,077 | 0.0% | 14.94% | +5.6% | |
| VERA | Vera Therapeutics, Inc.cl a | $77,883,000 | +54.0% | 2,914,776 | 0.0% | 4.55% | +51.9% | |
| RHHBY | New | Roche Holding AGadr | $70,764,000 | – | 1,369,011 | +100.0% | 4.13% | – |
| ASND | Ascendis Pharma A/Sadr | $67,241,000 | -15.6% | 499,824 | 0.0% | 3.93% | -16.7% | |
| SPY | New | SPDR S&P 500 ETF Trustput | $47,496,000 | – | 100,000 | +100.0% | 2.77% | – |
| AVTE | Aerovate Therapeutics, Inc. | $44,315,000 | -43.8% | 3,758,686 | 0.0% | 2.59% | -44.6% | |
| ABBV | Buy | Abbvie Inc | $42,247,000 | +43.7% | 312,018 | +14.5% | 2.47% | +41.8% |
| QQQ | New | Invesco QQQ Trust Series 1put | $39,785,000 | – | 100,000 | +100.0% | 2.32% | – |
| YMAB | Y-mAbs Therapeutics, Inc | $35,569,000 | -43.2% | 2,194,278 | 0.0% | 2.08% | -44.0% | |
| IWM | New | iShares Russell 2000 ETFput | $33,368,000 | – | 150,000 | +100.0% | 1.95% | – |
| RGNX | Buy | Regenxbio Inc | $32,964,000 | +516.3% | 1,008,081 | +690.1% | 1.92% | +507.3% |
| TVTX | Buy | Travere Therapeutics Inc | $32,308,000 | +204.7% | 1,040,858 | +138.0% | 1.89% | +200.5% |
| UTHR | Sell | United Therapeutics Corp | $28,037,000 | -31.6% | 129,754 | -41.6% | 1.64% | -32.5% |
| HRTX | Buy | Heron Therapeutics Inc | $26,781,000 | +8.9% | 2,933,351 | +27.5% | 1.56% | +7.3% |
| CCXI | Buy | ChemoCentryx Inc | $26,624,000 | +200.7% | 731,222 | +41.2% | 1.56% | +196.8% |
| BPMC | Buy | Blueprint Medicines Corp | $26,261,000 | +40.5% | 245,182 | +34.8% | 1.53% | +38.6% |
| ALGN | Sell | Align Technology Inc | $25,077,000 | -19.8% | 38,159 | -18.8% | 1.46% | -20.9% |
| HZNP | Buy | Horizon Therapeutics PLC | $23,900,000 | +38.5% | 221,792 | +40.8% | 1.40% | +36.6% |
| GH | Buy | Guardant Health Inc | $23,261,000 | +365.2% | 232,563 | +481.4% | 1.36% | +359.1% |
| XNCR | New | Xencor Inc | $21,546,000 | – | 537,030 | +100.0% | 1.26% | – |
| CYTK | Buy | Cytokinetics Inc | $21,166,000 | +38.8% | 464,366 | +8.8% | 1.24% | +36.9% |
| BCRX | New | BioCryst Pharmaceuticals Inc | $20,920,000 | – | 1,510,473 | +100.0% | 1.22% | – |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $20,822,000 | +163.3% | 951,226 | +129.9% | 1.22% | +159.8% |
| IRTC | New | iRhythm Technologies Inc | $19,876,000 | – | 168,882 | +100.0% | 1.16% | – |
| DXCM | Sell | Dexcom Inc | $17,399,000 | -14.6% | 32,404 | -13.0% | 1.02% | -15.8% |
| PTGX | Buy | Protagonist Therapeutics Inc | $16,493,000 | +212.7% | 482,257 | +62.0% | 0.96% | +208.7% |
| INBX | New | Inhibrx Inc | $16,100,000 | – | 368,679 | +100.0% | 0.94% | – |
| NXTC | Nextcure, Inc | $16,031,000 | -11.0% | 2,671,856 | 0.0% | 0.94% | -12.2% | |
| GRTX | Galera Therapeutics, Inc | $14,154,000 | -43.3% | 3,083,712 | 0.0% | 0.83% | -44.1% | |
| INZY | Inozyme Pharma, Inc. | $13,833,000 | -41.2% | 2,028,308 | 0.0% | 0.81% | -42.0% | |
| IMTX | Buy | Immatics NV | $13,798,000 | +121.9% | 1,026,623 | +114.7% | 0.81% | +119.0% |
| BOLT | Bolt Biotherapeutics, Inc. | $13,497,000 | -61.3% | 2,754,437 | 0.0% | 0.79% | -61.8% | |
| ISEE | Buy | Iveric Bio Inc | $13,356,000 | +130.1% | 798,789 | +123.5% | 0.78% | +126.7% |
| NCNA | Nucana Plcadr | $13,328,000 | -7.8% | 5,599,999 | 0.0% | 0.78% | -9.1% | |
| JNCE | Buy | Jounce Therapeutics Inc | $13,216,000 | +179.1% | 1,582,777 | +148.3% | 0.77% | +175.7% |
| IMGN | New | ImmunoGen Inc | $12,984,000 | – | 1,749,882 | +100.0% | 0.76% | – |
| AKUS | Akouos, Inc. | $12,878,000 | -26.8% | 1,515,074 | 0.0% | 0.75% | -27.8% | |
| INSM | Sell | Insmed Inc | $12,034,000 | -18.3% | 441,773 | -17.4% | 0.70% | -19.5% |
| FULC | Buy | Fulcrum Therapeutics Inc | $10,927,000 | +659.3% | 617,670 | +1111.0% | 0.64% | +650.6% |
| SRPT | Sell | Sarepta Therapeutics Inc | $10,872,000 | -25.3% | 120,732 | -23.2% | 0.64% | -26.2% |
| CLDX | Buy | Celldex Therapeutics Inc | $10,492,000 | +41.8% | 271,533 | +98.2% | 0.61% | +40.0% |
| CMPI | Checkmate Pharmaceuticals Inc | $10,351,000 | -27.7% | 3,606,707 | 0.0% | 0.60% | -28.7% | |
| PTGX | New | Protagonist Therapeutics Inccall | $10,281,000 | – | 300,600 | +100.0% | 0.60% | – |
| QURE | Buy | Uniqure NV | $10,267,000 | +307.3% | 495,025 | +528.7% | 0.60% | +302.7% |
| OBSV | ObsEva SA | $9,452,000 | -36.0% | 4,749,623 | 0.0% | 0.55% | -36.9% | |
| VIR | New | Vir Biotechnology Incput | $8,374,000 | – | 200,000 | +100.0% | 0.49% | – |
| BMRN | New | Biomarin Pharmaceutical Inc | $7,715,000 | – | 87,322 | +100.0% | 0.45% | – |
| ZYME | Sell | Zymeworks Inc | $6,437,000 | -46.0% | 392,712 | -4.4% | 0.38% | -46.7% |
| AGEN | Sell | Agenus Inc | $6,315,000 | -48.7% | 1,961,032 | -16.4% | 0.37% | -49.4% |
| Nucana Plcordinary shares | $5,712,000 | -7.8% | 2,400,000 | 0.0% | 0.33% | -9.0% | ||
| IFRX | New | Inflarx NV | $5,530,000 | – | 1,161,736 | +100.0% | 0.32% | – |
| ACET | New | Adicet Bio Inc | $5,439,000 | – | 310,988 | +100.0% | 0.32% | – |
| PTCT | Sell | PTC Therapeutics Inc | $5,275,000 | -38.4% | 132,448 | -42.4% | 0.31% | -39.3% |
| KURA | Sell | Kura Oncology Inc | $5,168,000 | -63.5% | 369,173 | -51.1% | 0.30% | -64.0% |
| SRRA | Buy | Sierra Oncology Inc | $4,615,000 | +1.9% | 212,281 | +2.8% | 0.27% | +0.7% |
| AXSM | New | Axsome Therapeutics Incput | $3,778,000 | – | 100,000 | +100.0% | 0.22% | – |
| NVCR | New | Novocure Ltdcall | $3,754,000 | – | 50,000 | +100.0% | 0.22% | – |
| ITCI | Sell | Intra-Cellular Therapies Inc | $2,979,000 | -64.9% | 56,915 | -75.0% | 0.17% | -65.3% |
| ICPT | New | Intercept Pharmaceuticals Inccall | $2,450,000 | – | 150,400 | +100.0% | 0.14% | – |
| KURA | New | Kura Oncology Inccall | $2,450,000 | – | 175,000 | +100.0% | 0.14% | – |
| CYT | Sell | Cyteir Therapeutics Inc | $2,040,000 | -52.8% | 179,450 | -27.1% | 0.12% | -53.5% |
| Buy | Marinus Pharmaceuticals Inc | $2,035,000 | +7.3% | 171,338 | +2.8% | 0.12% | +6.2% | |
| New | Mink Therapeutics Inc | $1,541,000 | – | 345,499 | +100.0% | 0.09% | – | |
| ALGS | Buy | Aligos Therapeutics Inc | $1,517,000 | -21.4% | 127,791 | +2.8% | 0.09% | -21.9% |
| SYBX | Synlogic Inc. | $1,391,000 | -20.7% | 574,972 | 0.0% | 0.08% | -22.1% | |
| PDSB | PDS Biotechnology Corporation | $1,155,000 | -45.6% | 142,635 | 0.0% | 0.07% | -46.8% | |
| FUSN | Fusion Pharmaceuticals Inc | $326,000 | -47.2% | 78,066 | 0.0% | 0.02% | -48.6% | |
| PODD | Insulet Corp | $284,000 | -6.3% | 1,066 | 0.0% | 0.02% | -5.6% | |
| EW | New | Edwards Lifesciences Corp | $182,000 | – | 1,406 | +100.0% | 0.01% | – |
| Exit | Intercept Pharmaceuticals Incall | $0 | – | -190,000 | -100.0% | -0.17% | – | |
| Exit | Novocure Ltdcall | $0 | – | -30,000 | -100.0% | -0.21% | – | |
| Exit | Iveric Bio Incput | $0 | – | -255,300 | -100.0% | -0.25% | – | |
| Exit | Protagonist Therapeutics Inccall | $0 | – | -300,000 | -100.0% | -0.32% | – | |
| AMRN | Exit | Amarin Corpadr | $0 | – | -1,069,968 | -100.0% | -0.32% | – |
| CTIC | Exit | CTI BioPharma Corp | $0 | – | -2,074,714 | -100.0% | -0.36% | – |
| XLRN | Exit | Acceleron Pharma Inc | $0 | – | -39,589 | -100.0% | -0.40% | – |
| ALXO | Exit | ALX Oncology Holdings Inc | $0 | – | -107,220 | -100.0% | -0.47% | – |
| Exit | ChemoCentryx Incput | $0 | – | -505,800 | -100.0% | -0.51% | – | |
| KDMN | Exit | Kadmon Holdings Inc | $0 | – | -1,046,312 | -100.0% | -0.54% | – |
| BIIB | Exit | Biogen Inc | $0 | – | -33,220 | -100.0% | -0.56% | – |
| MRTX | Exit | Mirati Therapeutics Inc | $0 | – | -56,900 | -100.0% | -0.60% | – |
| EXEL | Exit | Exelixis Inc | $0 | – | -488,414 | -100.0% | -0.61% | – |
| ZTS | Exit | Zoetis Inccl a | $0 | – | -76,000 | -100.0% | -0.87% | – |
| RETA | Exit | Reata Pharmaceuticals Inc | $0 | – | -157,488 | -100.0% | -0.94% | – |
| Exit | United Therapeutics Corpput | $0 | – | -94,500 | -100.0% | -1.03% | – | |
| Exit | Regeneron Pharmaceuticalsput | $0 | – | -30,000 | -100.0% | -1.08% | – | |
| Exit | Bristol-Myers Squibb Cocall | $0 | – | -400,000 | -100.0% | -1.40% | – | |
| Exit | Merck & Co Inccall | $0 | – | -600,000 | -100.0% | -2.67% | – | |
| AZN | Exit | AstraZeneca PLCadr | $0 | – | -1,128,272 | -100.0% | -4.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.